Cargando…

Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma

SIMPLE SUMMARY: The hemodilution of bone marrow aspirates is the main factor affecting the reliability of the determination of the minimal residual disease (MRD) resulting in multiple myeloma (MM). A bone marrow particle cell (BMPL) enrichment assay may be applied to overcome the problems caused by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Duanfeng, Zhang, Yanan, Tan, Shiming, Liu, Jing, Li, Xin, Zhang, Congming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563644/ https://www.ncbi.nlm.nih.gov/pubmed/36230860 http://dx.doi.org/10.3390/cancers14194937

Ejemplares similares

Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study
por: Zhang, Congming, et al.
Publicado: (2020)

Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium
por: Krzywdzińska, Agnieszka, et al.
Publicado: (2021)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
por: op Bruinink, Davine Hofste, et al.
Publicado: (2020)

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients
por: Mendonça de Pontes, Robéria, et al.
Publicado: (2021)

Flow Cytometric Evaluation of Cell Cycle Regulators (Cyclins and Cyclin-Dependent Kinase Inhibitors) Expressed on Bone Marrow Cells in Patients with Chronic Myeloid Leukemia and Multiple Myeloma
por: Toprak, Selami K, et al.
Publicado: (2012)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Immunophenotypic Characterization of Human Bone Marrow Mast Cells. A Flow Cytometric Study of Normal and Pathological Bone Marrow Samples
por: Escribano, Luis, et al.
Publicado: (1998)

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Flow Cytometric Analysis of Hematopoietic Populations in Rat Bone Marrow. Impact of Trauma and Hemorrhagic Shock
por: Francis, Wendy R., et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
por: Flores-Montero, J, et al.
Publicado: (2017)

“Friends and foes” of multiple myeloma measurable/minimal residual disease evaluation by next generation flow
por: Pacelli, Paola, et al.
Publicado: (2022)

Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
por: Buldini, Barbara, et al.
Publicado: (2019)

A Case of IgG4-related Disease With Bone Marrow Involvement: Bone Marrow Findings and Flow Cytometric Immunophenotyping of Plasma Cells
por: Kim, Han Joo, et al.
Publicado: (2021)

Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma
por: Blum, Agnieszka, et al.
Publicado: (2019)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
por: Yoroidaka, Takeshi, et al.
Publicado: (2021)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells
por: Vora, Ashni A., et al.
Publicado: (2021)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma
por: Okamoto, Haruya, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives
por: Mina, Roberto, et al.
Publicado: (2020)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
por: Keyel, Michelle E., et al.
Publicado: (2023)

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Ho, Matthew, et al.
Publicado: (2022)

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2014)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

Minimal residual disease negativity by next‐generation flow in non‐CR myeloma patients
por: Kim, Sung‐Min, et al.
Publicado: (2020)

MICy: a Novel Flow Cytometric Method for Rapid Determination of Minimal Inhibitory Concentration
por: Kállai, András, et al.
Publicado: (2021)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i3s2u55euqgteir9us1631gb71